[Clinical studies of intravenous drip infusion of micronomicin. Internal field infections].
Micronomicin sulfate (MCR) by intravenous drip infusion for internal field infections was studied in 30 cooperative research institutions and the following results were obtained. Clinical efficacy of MCR on respiratory tract infections was 79.4% for pneumonia, 51.5% for chronic bronchitis and 81.0% for respiratory tract infections associated with bronchiectasis, respectively, with a total effectiveness rate of 70.9%. MCR was effective on urinary tract infections with a rate of 85% and on septicemia with a rate of 80%. There were no cases of clinical symptoms seemed to be adverse reactions. Abnormal laboratory test values were noted in 13 out of 167 cases (7.8%), but all of them were transient without severe reactions observed. It is fully expected that MCR intravenous drip infusion for internal field infection is clinically effective.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin